perifosine
Small moleculeexperimental
Perifosine is a former drug candidate that was under development for a variety of cancer indications. It is an alkyl-phospholipid structurally related to miltefosine. Perifosine interrupts the PI3K/AKT/mTOR pathway by acting as an allosteric AKT inhibitor targeting the pleckstrin homology domain of AKT. It was being developed by Keryx Biopharmaceuticals who had licensed it from Æterna Zentaris Inc. — Wikipedia
Clinical trial activity
42 trials · 27 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
27
Phase 3
2
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00019656)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 2
- Central Nervous System Diseases · Phase 2
- Chondrosarcoma · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- Endometrial Neoplasms · Phase 2
- Gastrointestinal Stromal Tumors · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic-Phase · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 1
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 3
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 2
- Oligodendroglioma · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1- Mol. weight
- 461.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPerifosine ↗
- ChEMBLCHEMBL372764 ↗
Also known as
- d 21266
- d-21266
- krx-0401
- krx-0401
- octadecyl-(1,1-dimethyl-4-piperidylio)phosphate
- perifosine
- perifosine
- perifosine
- perifosine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02238496 | Phase 2 | Jul 1, 2014 | AEterna Zentaris, Columbia University, Pfizer |
| NCT01224730 | Phase 1 | Jan 1, 2012 | AEterna Zentaris, Keryx |
| NCT01097018 | Phase 3 | Apr 1, 2010 | AEterna Zentaris, SCRI Development Innovations |
| NCT01051557 | Phase 1/Phase 2 (Phase 2) | Jan 27, 2010 | Cornell University, National Cancer Institute (NCI) |
| NCT01049841 | Phase 1 | Jan 1, 2010 | AEterna Zentaris, Cornell University, Duke University, Pfizer, University of Wisconsin |
| NCT01002248 | Phase 3 | Dec 1, 2009 | AEterna Zentaris, Harvard University |
| NCT01048580 | Phase 1 | Oct 1, 2009 | AEterna Zentaris, SCRI Development Innovations |
| NCT00873457 | Phase 2 | Aug 1, 2009 | Duke University, Keryx |
| NCT00776867 | Phase 1 | Oct 1, 2008 | AEterna Zentaris, Cornell University, Duke University, University of Wisconsin |
| NCT00847366 | N/A | May 1, 2008 | AEterna Zentaris |
| NCT00498966 | Phase 2 | Jul 1, 2007 | AEterna Zentaris, Nevada Cancer Institute |
| NCT00448721 | Phase 2 | Mar 1, 2007 | AEterna Zentaris, Harvard University |
| NCT00431054 | Phase 1 | Feb 1, 2007 | Keryx, University of Texas at Houston |
| NCT00415064 | Phase 1 | Dec 1, 2006 | AEterna Zentaris, University of Michigan |
| NCT00401388 | Phase 2 | Nov 1, 2006 | AEterna Zentaris, Sarcoma Alliance for Research through Collaboration, University of Texas at Houston |
| NCT00391560 | Phase 2 | Oct 1, 2006 | AEterna Zentaris, University of Texas at Houston |
| NCT00399152 | Phase 1 | Oct 1, 2006 | AEterna Zentaris |
| NCT00398814 | Phase 1 | Oct 1, 2006 | AEterna Zentaris |
| NCT00398710 | Phase 2 | Oct 1, 2006 | AEterna Zentaris, Harvard University |
| NCT00422656 | Phase 2 | Sep 1, 2006 | Harvard University |
Showing 20 of 42 trials
Page 1 / 3
Organizations
Research & Development (27)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AEterna Zentaris | For profit | 24 | 21 | 4 | 2004 |
| National Cancer Institute (NCI) | Government | 13 | 7 | 2 | 1999 |
| Harvard University | Academic/Hospital | 6 | 1 | 2 | 2005 |
| Keryx | For profit | 5 | 0 | 2 | 2004 |
| Cornell University | Academic/Hospital | 4 | 3 | 2 | 2006 |
| University of Texas at Houston | Academic/Hospital | 4 | 1 | 2 | 2006 |
| University of Wisconsin | Academic/Hospital | 4 | 1 | 2 | 2000 |
| Duke University | Academic/Hospital | 3 | 1 | 2 | 2008 |
| SCRI Development Innovations | For profit | 3 | 0 | 3 | 2004 |
| Canadian Cancer Trials Group | Academic/Hospital | 2 | 2 | 1 | 2003 |
| Columbia University | Academic/Hospital | 2 | 1 | 1 | 2006 |
| Pfizer | For profit | 2 | 0 | 2 | 2010 |
| University of Toronto | Academic/Hospital | 2 | 2 | 1 | 2003 |
| AOI Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2006 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Nevada Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Online Collaborative Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Queen's University, Belfast | Academic/Hospital | 1 | 0 | 1 | 2003 |
27 organizations
Page 1 / 2